Abstract:Osteosarcoma is a rare type of bone cancer, and half of the cases affect children and adolescents younger than 20 years of age. Despite intensive efforts to improve both chemotherapeutics and surgical management, the clinical outcome for metastatic osteosarcoma remains poor. Transforming growth factor β (TGF-β) is one of the most abundant growth factors in bones. The TGF-β signaling pathway has complex and contradictory roles in the pathogenesis of human cancers. TGF-β is primarily a tumor suppressor that inhibits proliferation and induces apoptosis of premalignant epithelial cells. In the later stages of cancer progression, however, TGF-β functions as a metastasis promoter by promoting tumor growth, inducing epithelial-mesenchymal transition (EMT), blocking antitumor immune responses, increasing tumor-associated fibrosis, and enhancing angiogenesis. In contrast with the dual effects of TGF-β on carcinoma (epithelial origin) progression, TGF-β seems to mainly have a pro-tumoral effect on sarcomas including osteosarcoma (mesenchymal origin). Many drugs that target TGF-β signaling have been developed: neutralizing antibodies that prevent TGF-β binding to receptor complexes; ligand trap employing recombinant Fc-fusion proteins containing the soluble ectodomain of either type II (TβRII) or the type III receptor ((TβRIII), preventing TGF-β from binding to its receptors; antisense nucleotides that reduce TGF-β expression at the transcriptional/translational level; small molecule inhibitors of serine/threonine kinases of the type I receptor (TβRI) preventing downstream signaling; and vaccines that contain cell lines transfected with TβRII antisense genes, or target furin convertase, resulting in reduced TGF-β signaling. TGF-β antagonists have been shown to have effects on osteosarcoma in vitro and in vivo. One of the small molecule TβRI inhibitors, Vactosertib, is currently undergoing a phase 1/2 clinical trial to evaluate its effect on osteosarcoma. Several phase 1/2/3 clinical trials have shown TGF-β antagonists are safe and well tolerated. For instance, Luspatercept, a TGF-β ligand trap, has been approved by the FDA for the treatment of anemia associated with myeloid dysplastic syndrome (MDS) with ring sideroblasts/mutated SF3B1 with acceptable safety. Clinical trials evaluating the long-term safety of Luspatercept are in process.

Effects of Transforming Growth Factor Beta 1 on the Growth of Rhabdomyosarcoma Cell Line RD.

[Regulation of Growth Inhibition by Transforming Growth Factor Beta1 in Rhabdomyosarcoma RD Cell Line].

[Effects of Transforming Growth Factor-Beta/smad Signaling on the Growth and Apoptosis of Human Rhabdomyosarcoma Cell Line RD].

Differential Effects of Transforming Growth Factor on Cell Cycle Regulatory Molecules in Human Myeloid Leukemia Cells

Systematic Analysis of the TGF‐β/Smad Signalling Pathway in the Rhabdomyosarcoma Cell Line RD

Transforming Growth Factor Β Inhibits Growth of More Differentiated Myeloid Leukemia Cells and Retinoblastoma Protein Phosphorylation at Serine 795

Transforming Growth Factor: Signal Transduction Pathways, Cell Cycle Mediation, And Effects On Hematopoiesis

Effect on Cell Growth,c-mycmRNA Expression and Telomerase Activity by Transforming Growth Factor-β1 in Malignant Lymphoma and Leukemia Cell Line

Cell cycle and transcriptional control of human myeloid leukemic cells by transforming growth factor beta.

Effect of Transforming Growth Factor Β1 on Cell Growth and C-Myc Gene Expression on Lymphoma Cell Line

Smad4 and ERK2 Stimulated by Transforming Growth Factor Beta1 in Rhabdomyosarcoma.

Smad4 And Erk2 Stimulated By Transforming Growth Factor Betal In Rhabdomyosarcoma

Transforming Growth Factor Β Inhibits the Phosphorylation of Prb at Multiple Serine/Threonine Sites and Differentially Regulates the Formation of Prb Family–E2F Complexes in Human Myeloid Leukemia Cells

Effect of TGF-β1 on Cell Proliferation and C-Myc Expression in Burkitt Lymphoma Cell Line

Effect of Transforming Growth Factor-Beta 1 on the Proliferation of Breast Cancer Cell Lines and T Lymphocyte Transducted Cellular Immuno-Activity

Transforming Growth Factor Β1 Enhances the Invasiveness of Human Glioma Cell Line Via ERK/MAPK Pathway

Inhibitory Effect of Bone Morphogenetic Protein-2 on the Proliferation of Giant Cell Tumor of Bone Stromal Cells in Vitro.

Effects of TGF-β1 Autocrine Blockage on the Osteosarcoma Cells

TGF-β Induces Growth Suppression in Multiple Myeloma MM.1S Cells Via E2F1.

Effects of Rnai-Mediated Smad4 Silencing on Growth and Apoptosis of Human Rhabdomyosarcoma Cells

Targeting transforming growth factor beta signaling in metastatic osteosarcoma